Jeffrey S. Wiezorek

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

Medicine, Oncology, Pharmacology +12

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +15

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Frederick L. Locke, John M. Rossi, Sattva S. Neelapu et al. · Blood Advances · 2020 · 455 citations · Full text

Medicine, Immunology, Oncology +17

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Alex Parker et al. · Clinical Cancer Research · 2013 · 249 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Mutant <i>KRAS</i> Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Marc Peeters, Jean‐Yves Douillard, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2012 · 233 citations · Full text

Medicine, Oncology, Pharmacology +17